PubRank

G F Pineo

Author PubWeight™ 60.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prevention of venous thromboembolism. Chest 2001 5.59
2 Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992 3.23
3 Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001 2.37
4 Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med 1996 2.24
5 Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000 1.72
6 The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med 1997 1.53
7 Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999 1.50
8 Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000 1.48
9 Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med 1994 1.44
10 Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000 1.34
11 Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997 1.34
12 The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med 1973 1.30
13 Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992 1.29
14 Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992 1.24
15 Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery 1994 1.22
16 Unexpected vitamin K deficiency in hospitalized patients. Can Med Assoc J 1973 1.09
17 A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med 1994 1.08
18 Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci 1974 1.06
19 Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1998 1.05
20 Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol 1970 1.04
21 Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. N Engl J Med 1974 1.02
22 The nature of experimental second-set kidney transplant rejection. 1. The role of coagulation in hyperacute (second-set) renal allotransplant rejection in dogs. Br J Exp Pathol 1970 1.01
23 Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001 1.00
24 The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation 1975 0.99
25 Aging and heparin-related bleeding. Arch Intern Med 1996 0.96
26 Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012 0.96
27 Henoch-Schönlein purpura occurring in three members of a family. Can Med Assoc J 1973 0.94
28 The low-probability lung scan. A need for change in nomenclature. Arch Intern Med 1995 0.91
29 Low molecular weight heparin treatment of venous thromboembolism. Prog Cardiovasc Dis 1994 0.88
30 Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 2001 0.87
31 Therapeutic use of low-molecular-weight heparins. Haemostasis 1993 0.85
32 Preleukaemia and reticulocytosis: a case report with in vitro evidence for abnormal reticulocyte maturation. Scand J Haematol 1978 0.83
33 Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost 1995 0.82
34 Different effects of heparin in males and females. Clin Invest Med 1998 0.82
35 Massive colchicine overdose: a report on the toxicity. Am J Med Sci 1976 0.82
36 Von Willebrand's syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammopathy. Blood 1973 0.82
37 Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII. Br J Haematol 1973 0.81
38 The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis 1998 0.80
39 Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med 1997 0.79
40 Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. J Thromb Haemost 2011 0.79
41 Cost-effectiveness of currently accepted strategies for pulmonary embolism diagnosis. Semin Thromb Hemost 2001 0.79
42 Extended prophylaxis against venous thromboembolism following total hip and knee replacement. Haemostasis 1999 0.77
43 Venous thromboembolism and cancer. Baillieres Clin Haematol 1998 0.77
44 Prophylaxis of venous thromboembolism in brain tumor patients. J Neurooncol 1994 0.77
45 Intermittent pneumatic compression for the prevention of venous thromboembolism. Chest 1996 0.75
46 Impedance plethysmography for suspected deep-vein thrombosis. Arch Intern Med 1995 0.75
47 Impedance plethysmography and DVT diagnosis. Ann Intern Med 1993 0.75
48 Angioedema-like skin lesions associated with lymphoproliferative disease. Can Med Assoc J 1982 0.75
49 Hirudin versus heparin and low-molecular-weight heparin: and the winner is... J Lab Clin Med 1998 0.75
50 Disorders of pulmonary circulation. Curr Opin Pulm Med 1997 0.75
51 Chronic idiopathic thrombocytogenic purpura. Can Fam Physician 1984 0.75
52 Disorders of pulmonary circulation. Curr Opin Pulm Med 1998 0.75
53 Disorders of pulmonary circulation. Curr Opin Pulm Med 1999 0.75
54 Low-molecular-weight heparin in the treatment of venous thromboembolism. Semin Thromb Hemost 2000 0.75
55 Red cell flexibility and pressure-flow relations in isolated lungs. J Appl Physiol 1973 0.75
56 Therapeutic use of low molecular weight heparins: knowledge to date and their application to therapy. Semin Thromb Hemost 1994 0.75
57 Treatment of venous thromboembolism with low molecular weight heparins. Hematol Oncol Clin North Am 1992 0.75
58 The relevance of platelet and fibrinogen kinetics and coagulation studies to extent of disease and performance status in patients with adenocarcinoma. Med Pediatr Oncol 1980 0.75
59 Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme. Int Angiol 1998 0.75
60 Treatment and prevention of venous thromboembolism. Semin Thromb Hemost 1998 0.75
61 Low-molecular-weight heparins for the treatment of venous thromboembolism. Ann Med 1993 0.75
62 Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring. Int Angiol 1998 0.75
63 Papular leukemids. Cutis 1986 0.75
64 Pulmonary vascular disease. Curr Opin Pulm Med 2001 0.75
65 Therapeutic use of low molecular weight heparins: the knowledge to date as applied to therapy. Semin Thromb Hemost 1993 0.75
66 Prophylaxis of deep venous thrombosis and pulmonary embolism. Current recommendations. Med Clin North Am 1998 0.75
67 Pulmonary vascular disease. Curr Opin Pulm Med 1995 0.75
68 The role of newer diagnostic techniques in the diagnosis of pulmonary embolism. Curr Opin Pulm Med 1999 0.75
69 An approach to immunotherapy using antibody to IgE in mast cell leukemia. Cancer 1976 0.75
70 Low-molecular-weight heparin therapy and mortality. Semin Thromb Hemost 1997 0.75
71 Residency training programme in internal medicine at McMaster University. J R Coll Physicians Lond 1972 0.75
72 Long term outpatient prophylaxis for venous thromboembolism. Semin Thromb Hemost 1999 0.75
73 Essential thrombocythemia and complications of pregnancy. Am J Hematol 1991 0.75
74 Current concepts of anticoagulation therapy. Clin Chest Med 1995 0.75
75 Disorders of pulmonary circulation: pulmonary vascular disease. Curr Opin Pulm Med 2000 0.75
76 Pulmonary vascular disease. Curr Opin Pulm Med 1996 0.75
77 Flexibility of red cells and pressure-flow relations in isolated lungs. Clin Sci 1970 0.75